1 report

  • filgrastim
  • Filgrastim biosimilar

“Oncology drugs report - Neupogen and Neulasta - filgrastim franchise - 1991-2015 analysis; 2016-2021 expectations” is a comprehensive report on Neupogen and Neulasta, two market leading drugs (by 2015 sales) used in the treatment of chemotherapy-induced febrile neutropenia. These drugs, both belonging to biotech giant Amgen, fall under...

  • Filgrastim
  • North America
  • United States
  • Demand
  • Hospira, Inc.